NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Cellectis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On September 14, 2026, Cellectis announced that it would prioritize in vivo gene editing therapies (HEAL-101 and HEAL-201) over CAR-T cell therapies. The Company concurrently announced that it plans to discontinue the development of CAR-T cell therapies lasme-cel and eti-cel. In an accompanying conference call, the Company’s Chief Medical Officer, Adrian Kilcoyne said that “Cellectis is not able [to] finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have.”
On this news, Cellectis’s American Depositary Receipt (“ADR”) price fell $1.27 per ADR, or 40.97%, to close at $1.83 per ADR on September 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
